Location Directory

Clinical trials in San Antonio, Texas

This page shows live ClinicalTrials.gov search results for San Antonio, Texas, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

3164

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Advanced Solid Tumor, Metastatic Solid Tumor
Interventions: IPN01203; Biological
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 4
States / cities: Grand Rapids, Michigan • Nashville, Tennessee • Houston, Texas + 1 more

Conditions: Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer, Breast Cancer, Colon Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Prostate Cancer, Uterine Cancer, Cervix Cancer, Ovarian Cancer, Kidney Cancer, Bladder Cancer, Thyroid Cancer, Melanoma, Sarcoma, Advanced Cancer, Metastatic Cancer, Refractory Cancer, Non Small Cell Lung Cancer, Merkel Cell Carcinoma
Interventions: SNS-101 (anti-VISTA), Cemiplimab; Drug
Lead sponsor: Sensei Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 10
States / cities: Los Angeles, California • Aurora, Colorado • Louisville, Kentucky + 7 more

Conditions: Prostatic Neoplasms
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 21 Years and older · Male only
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2032
U.S. locations: 10
States / cities: San Francisco, California • Stanford, California • Atlanta, Georgia + 5 more

Conditions: Solid Tumor, Adult
Interventions: KQB198, Osimertinib, Amivantamab; Drug
Lead sponsor: Kumquat Biosciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 9
States / cities: Denver, Colorado • Orlando, Florida • Sarasota, Florida + 6 more

Conditions: Breast Cancer
Interventions: Ultrahypofractionated Radiation, Moderately Hypofractionated Radiation; Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 768 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 5
States / cities: Loveland, Colorado • Jacksonville, Florida • Voorhees Township, New Jersey + 2 more

Conditions: Influenza, Human
Interventions: aQIV or aTIV, QIV or TIV; Biological
Lead sponsor: Seqirus; Industry
Eligibility: 65 Years and older
Enrollment: 38,769 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 111
States / cities: Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 96 more

Conditions: Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Synchronous Bilateral Breast Carcinoma
Interventions: Health Education Program, Weight Loss Intervention; Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3,177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2030
U.S. locations: 1464
States / cities: Daphne, Alabama • Mobile, Alabama • Anchorage, Alaska + 921 more

Conditions: Chronic Kidney Disease, Hemodialysis Access, Arteriovenous Fistula, End Stage Renal Disease (ESRD)
Interventions: Velocity Percutaneous Arteriovenous Fistula; Device
Lead sponsor: Venova Medical; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 13
States / cities: Dothan, Alabama • Concord, California • Riverside, California + 9 more

Conditions: Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer
Interventions: SV-BR-1-GM, Cyclophosphamide, Interferon infiltration of the inoculation site, Retifanlimab, Treatment of Physician's Choice; Biological · Drug
Lead sponsor: BriaCell Therapeutics Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 79
States / cities: Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 60 more

Conditions: Plasma Cell Myeloma Recurrent
Interventions: Isatuximab IV, Isatuximab SC, Dexamethasone, Pomalidomide, Montelukast, Paracetamol / Acetaminophen, Diphenhydramine, Methylprednisolone; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 531 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 13
States / cities: Aurora, Colorado • Jacksonville, Florida • Plantation, Florida + 10 more

Conditions: Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck, Unresectable Head and Neck Squamous Cell Carcinoma
Interventions: Combination Treatment of PDS0101 and Pembrolizumab, Pembrolizumab Monotherapy; Combination Product · Drug
Lead sponsor: PDS Biotechnology Corp.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 28
States / cities: Phoenix, Arizona • Greenbrae, California • Orange, California + 24 more

Conditions: Hidradenitis Suppurativa
Interventions: Lutikizumab, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years and older
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 73
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 64 more

Clinical trials in San Antonio, Texas

Filter and sort this location

Live official records

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Prostate Active Surveillance Study

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast Cancer

A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age

Breast Cancer WEight Loss Study (BWEL Study)

Pivotal Study of the Velocity™ pAVF System

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM

Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa